SCHEMBL4244346

SCHEMBL4244346

COc1ccc(C(C)(C)C)cc1NC(=O)Nc1ccc(Cc2ccncc2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.69
LMNA P02545 6/20 0.69
MEN1 O00255 4/20 0.69
KMT2A Q03164 4/20 0.69
RAB9A P51151 2/20 0.68
POLB P06746 2/20 0.68
SMN1; SMN2 Q16637 4/20 0.65
HTT P42858 4/20 0.57
HSP90AA1 P07900 1/20 0.57
RECQL P46063 1/20 0.57
GAA P10253 1/20 0.56
RAF1 P04049 2/20 0.54
ALDH1A1 P00352 3/20 0.53
MAPK14 Q16539 2/20 0.53
NPSR1 Q6W5P4 2/20 0.53
ERBB2 P04626 1/20 0.53
MAPK11 Q15759 1/20 0.53
CYP1A2 P05177 1/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2D6 P10635 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4238045 0.90 MEN1 (0.67) MAPTLMNAMEN1KMT2ARAB9A
SCHEMBL4238744 0.89 MEN1 (0.57) MAPTLMNAMEN1KMT2ARAB9A
SCHEMBL4238737 0.86 RAF1 (0.67) MAPTLMNAMEN1KMT2ASMN1; SMN2
SCHEMBL4243364 0.85 MAPT (0.57) MAPTLMNAMEN1KMT2ARAB9A
SCHEMBL4238004 0.80 MAPT (0.75) MAPTLMNAMEN1KMT2ARAB9A
SCHEMBL4251022 0.78 MAPT (0.65) MAPTLMNAMEN1KMT2ARAB9A
SCHEMBL257978 0.77 RAF1 (0.65) MAPTLMNAMEN1KMT2ARAB9A
SCHEMBL936531 0.77 MAPK14 (0.54) MAPTLMNAMEN1KMT2ARAB9A
SCHEMBL1492785 0.77 PSEN1 (0.57) MAPTLMNAMEN1KMT2ARAB9A
SCHEMBL4244650 0.76 RAF1 (0.63) MAPTLMNAMEN1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090093526-A1 INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS BAYER HEALTHCARE LLC 2009-04-09 US claimed
JP-3887769-B2 2007-02-28 JP claimed
EP-1616865-A1 Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas Bayer Pharmaceuticals Corporation (US) 2006-01-18 EP claimed
EP-1042305-B1 INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS BAYER PHARMACEUTICALS CORP (US) 2005-06-08 EP claimed
US-20040102636-A1 Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas BAYER CORPORATION 2004-05-27 US claimed
EP-1042305-A4 INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS BAYER AG (US) 2003-05-14 EP claimed
JP-2001526276-A 2001-12-18 JP claimed
EP-1042305-A1 INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS Bayer Corporation (US) 2000-10-11 EP claimed
WO-1999032463-A1 INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS BAYER CORPORATION (US) 1999-07-01 WO claimed
US-20120270878-A1 INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS BAYER HEALTHERCARE LLC (US) 2012-10-25 US disclosed
US-7517880-B2 Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas BAYER PHARMACEUTICALS CORPORATION (US) 2009-04-14 US disclosed
US-20090093526-A1 INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS BAYER HEALTHCARE LLC 2009-04-09 US disclosed
EP-1539121-A4 METHODS OF PROMOTING OSTEOGENESIS SCIOS INC (US) 2008-08-13 EP disclosed
EP-1545535-A4 TREATMENT OF PAIN BY INHIBITION OF P38 MAP KINASE SCIOS INC (US) 2008-06-04 EP disclosed
WO-2004024083-A2 METHODS OF BONE HEALING UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) 2004-03-25 WO disclosed
WO-2004021988-A2 TREATMENT OF PAIN BY INHIBITION OF P38 MAP KINASE SCIOS INC. (US) 2004-03-18 WO disclosed
WO-2004019873-A2 METHODS OF PROMOTING OSTEOGENESIS SCIOS INC. (US) 2004-03-11 WO disclosed
EP-1042305-A4 INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS BAYER AG (US) 2003-05-14 EP disclosed
EP-1042305-A1 INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS Bayer Corporation (US) 2000-10-11 EP disclosed
WO-1999032463-A1 INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS BAYER CORPORATION (US) 1999-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093526-A1 INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS MAP2K2, MAPK1, MAP2K1 MAPT 618/4885LMNA 4398/4885MEN1 4566/4885
US-20040102636-A1 Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas MAP2K2, MAPK1, MAP2K1 MAPT 618/4885LMNA 4398/4885MEN1 4566/4885
US-20120270878-A1 INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS MAP2K2, MAPK1, MAP2K1 MAPT 618/4885LMNA 4398/4885MEN1 4566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.